In Hindsight, Savara Wishes It Led With Patient-Reported Secondary Endpoint For Molgradex
Orphan lung disease firm tries to sell Phase III setback in aPAP as a “successful failed study” but investors disagree, cutting Savara’s share price by three-quarters. Biotech hopes to talk with regulators after deeper dive into dataset.
You may also be interested in...
Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies
Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials. World's largest trial for health workers starts.
Italfarmaco and Neupharma plan to collaborate on the development of a new inhaled formulation of a Gram-positive targeted antibiotic for MRSA infections in cystic fibrosis.
Although small patient base offers modest revenue opportunity, the Nulibry approval enables BridgeBio to get commercial operations underway.